Black Men Experience More Treatment Regret With Prostate Cancer
FRIDAY, Dec. 4, 2020 -- African-American men with prostate cancer suffer worse decisional regret than non-African-American men, according to a study published online Nov. 23 in The Journal of Urology.
Molly E. DeWitt-Foy, M.D., from the Cleveland Clinic, and colleagues assessed sources of regret with a focus on racial disparities among 1,112 patients with localized prostate cancer treated at the Cleveland Clinic between 2010 and 2016. The analysis included survey responses from 378 participants.
The researchers found that African-American men had worse decisional regret than non-African-American men, even when adjusting for relevant covariates (odds ratio, 2.46). Medical mistrust and masculinity scores on the Prostate Cancer Beliefs Questionnaire were higher for African-American men. Both of these scores predicted worse decisional regret independent of race (odds ratios, 1.415 and 1.350, respectively).
"This novel survey may facilitate identifying targets to reduce racial disparities in prostate cancer," the authors write.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Read this next
THURSDAY, Jan. 21, 2021 -- For men with newly diagnosed prostate cancer on active surveillance, adherence to the Mediterranean diet (MedD) is associated with a lower risk for...
TUESDAY, Jan. 12, 2021 -- Increased coffee consumption is associated with a reduced risk for prostate cancer, according to a review and meta-analysis published online Jan. 11 in...
MONDAY, Dec. 21, 2020 -- Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. Food...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.